Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 1, 2012
Previous Article Next Article

A self-immolative dendritic glucuronide prodrug of doxorubicin

Author affiliations

Abstract

The first self-immolative dendritic glucuronide prodrug of doxorubicin was studied with the aim to target β-glucuronidase overexpressed in the microenvironment of numerous tumors. This compound includes a chemical amplifier programmed to release two molecules of doxorubicin after a single enzymatic activation step. Upon β-glucuronidase activation, the dendritic prodrug was twice more toxic than its monomeric counterpart against H661 lung cancer cells.

Graphical abstract: A self-immolative dendritic glucuronide prodrug of doxorubicin

Back to tab navigation

Supplementary files

Article information


Submitted
29 Jul 2011
Accepted
21 Sep 2011
First published
19 Oct 2011

Med. Chem. Commun., 2012,3, 68-70
Article type
Concise Article

A self-immolative dendritic glucuronide prodrug of doxorubicin

M. Grinda, J. Clarhaut, B. Renoux, I. Tranoy-Opalinski and S. Papot, Med. Chem. Commun., 2012, 3, 68
DOI: 10.1039/C1MD00193K

Search articles by author

Spotlight

Advertisements